Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.39 |
| ▸ | BTK | Q06187 | 4/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539061 | 0.86 | MTOR (0.38) | DYRK1ATRPA1IRAK4PIK3CAMTOR | |
| SCHEMBL17610067 | 0.85 | DYRK1A (0.41) | DYRK1AMAP3K12BTKSMPD3 | |
| SCHEMBL21861329 | 0.83 | MTOR (0.36) | TRPA1MAP3K12IRAK4PIK3CAMTOR | |
| SCHEMBL17609895 | 0.83 | TRPA1 (0.41) | TRPA1MAP3K12BTKSMPD3IRAK4 | |
| SCHEMBL17201970 | 0.82 | PIK3CA (0.35) | TRPA1MAP3K12IRAK4PIK3CAMTOR | |
| SCHEMBL17202033 | 0.82 | TRPA1 (0.42) | TRPA1IRAK4PIK3CAMTORPIK3R1 | |
| SCHEMBL17210409 | 0.81 | PIK3CA (0.40) | DYRK1AIRAK4PIK3CAMTORPIK3R1 | |
| SCHEMBL23073664 | 0.79 | ROCK1 (0.41) | DYRK1APIK3CAMTORPIK3R1 | |
| SCHEMBL17201976 | 0.77 | MAP3K12 (0.34) | DYRK1ATRPA1MAP3K12IRAK4PIK3CA | |
| SCHEMBL17619571 | 0.77 | MAP3K12 (0.44) | DYRK1ATRPA1MAP3K12BTKSMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| EP-3193880-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3134410-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | DYRK1A 3580/4885TRPA1 2/4885MAP3K12 2163/4885 |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPA1, TRPV1, TRPV2 | DYRK1A 2860/4885TRPA1 1/4885MAP3K12 1885/4885 |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPA1, TRPV1, TRPV2 | DYRK1A 2860/4885TRPA1 1/4885MAP3K12 1885/4885 |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | DYRK1A 3580/4885TRPA1 2/4885MAP3K12 2163/4885 |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | DYRK1A 3580/4885TRPA1 2/4885MAP3K12 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.